Abstract Tissue engineering and cell therapy require large-scale production of homogeneous populations of lineage-restricted progenitor cells that easily can be induced to differentiate into a specific tissue. We have developed straightforward protocols for the establishment of human embryonic stem (hES) cell-derived mesenchymal progenitor (hES-MP) cell lines. The reproducibility was proven by derivation of multiple hES-MP cell lines from 10 different hES cell lines. To illustrate clinical applicability, a xeno-free hES-MP cell line was also derived. None of the markers characteristic for undifferentiated hES cells were detected in the hES-MP cells. Instead, these cells were highly similar to mesenchymal stem cells with regard to morphology and expression of markers. The safety of hES-MP cells following transplantation was studied in severely combined immunodeficient (SCID) mice. The implanted hES-MP cells gave rise to homogeneous, well-differentiated tissues exclusively of mesenchymal origin and no teratoma formation was observed. These cells further have the potential to differentiate toward the osteogenic, adipogenic, and chondrogenic lineages in vitro. The possibility of easily and reproducibly generating highly expandable hES-MP cell lines from well-characterized hES cell lines with differentiation potential into several mesodermal tissues entails an enormous potential for the field of regenerative medicine.
Introduction
The successful isolation and culturing of human embryonic stem (hES) cells (Thomson et al., 1998 ) started a new field of research and has raised expectations that hES cells may provide a unique source of functional human cells for future cell therapy and tissue engineering. Since hES cell lines can be expanded in vitro without an apparent limit in the number of cell doublings and also have the potential to differentiate into derivatives of all three embryonic germ layers (pluripotency), they are a potentially valuable source of cells where autologous cells cannot be used. Some progress has been made in directing hES cell differentiation toward specific cell types such as neural cells (Carpenter et al., 2001) , hepatocyte-like cells (Lavon et al., 2004) , pancreatic cells (D'Amour et al., 2006) , cardiomyocytes (Kehat et al., 2003) , or connective tissue cells (Sottile et al., 2003) . However, the direct derivation of pure populations of functionally differentiated cells from hES cells still poses a challenge and there is a significant risk that the transplantation of undifferentiated hES cells may lead to tumor formation in the recipients. Progenitor cells are immature cells in an intermediate stage of development, i.e., between stem cells and fully mature cells. Like stem cells, progenitor cells have a capacity for self-renewal and differentiation, but these properties are more limited, i.e., progenitor cells have a more finite lifespan and give rise to a more lineagerestricted progeny (multipotency). From a safety aspect, the application of progenitor cells instead of undifferentiated hES cells for therapeutic purposes is favorable since the differentiation pathway is already partly determined and the risk of tumor formation should therefore be reduced. From a technical point of view, progenitor cultures are expected to be more stable and easier to scale up in vitro than undifferentiated hES cells, which would provide an advantage for bulk production of cells for therapy.
Of great interest in this context is the functionality and phenotype of the progenitors during embryogenesis and early human development. In human, the exact cellular interactions during embryogenesis and the properties required for normal maturation into functional cells and tissues during the early stages are sparsely explored. Instead parallels are often drawn to other species which can be more easily examined (Kerszberg and Wolpert, 2000) . During the allocation of cells to the three germ layers, the embryonic mesoderm develops from the primitive streak by an epithelial-mesenchymal transition process (Ullmann et al., 2007) . This development starts around Days 13-15 when cells migrate through the primitive streak to form the mesodermal layer. The extraembryonic mesoderm might have a dual origin developing through extraembryonic endoderm and the yolk sac or as a branching from the actual embryonic mesoderm. Segmentation of the paraxial mesoderm into somites continues to separate the lateral plate mesoderm into somatic and splanchnic mesoderm. The further development toward cartilage and even more complex organized structures like joints is thought to start with interrupted condensed mesenchymal structures but the exact mechanisms for this development remain to be fully explored (Pacifici et al., 2006) . Theoretically, mesenchymal progenitors derived from hES cells should have the developmental potential to recapitulate these processes and research to develop germ-layer-specific progenitor cells from hES cells has been ongoing. With respect to the mesoderm, progenitor cell lines have been derived from hES cells by transfection with human telomerase reverse transcriptase (Xu et al., 2004) , by coculture with mouse OP9 cells (Barberi et al., 2005) , by fluorescence-activated cell sorting (Lian et al., 2006) or by manual selection of cell populations (Stojkovic et al., 2005; Olivier et al., 2006) .
We have developed optimized protocols allowing the simple and reproducible derivation of mesenchymal progenitor (hES-MP) cell lines from undifferentiated hES cells. The protocols do not require cell transfection, coculture, cell sorting, or subjective manual selection and give rise to highly similar hES-MP cell lines with a mesenchymal morphology, extended in vitro expandability and the potential to give rise to derivates of the mesoderm. We further demonstrate the universal applicability and reproducibility of the method by deriving multiple hES-MP cell lines from 10 different parental hES cell lines and show for the first time that derivation and culture of hES-MP cells could be performed under xeno-free conditions from a xeno-free parental hES cell line. With respect to future clinical suitability we show that hES-MP cells consistently survive transplantation and develop into several connective tissues in vivo, without generating teratoma.
Results

Derivation and culture of hES-MP cell lines
The robust method developed to derive hES-MP cell lines from undifferentiated hES cell lines is based on the application of a selective pressure which favors fast growing cells with an ability to attach and proliferate in feeder-free monolayer culture. These conditions provide a growth advantage for hES-MP cells while slow-growing differentiated cell types as well as undifferentiated hES cells were eliminated.
Consecutive enzymatic passaging as single cell suspensions under the described conditions reproducibly led to the derivation of morphologically homogeneous hES-MP cell lines from high-density cultures of pluripotent undifferentiated hES cells within 2-3 passages (Fig. 1) . The highdensity plated hES cells initially gave rise to a mixed population of various differentiating cell types (Fig. 1a) . Each consecutive passage decreased the amount of contaminating cell types and the cultures became increasingly homogeneous (Figs. 1b-d) . The hES-MP cells phenotypically resemble mesenchymal cells with typical fibroblast like morphology, i.e., elongated spindle-shaped cell morphology with branching pseudopodi (Fig. 1e) . The morphologies of both hES-MP cells and mesenchymal stem cells (MSCs) are significantly different from those of undifferentiated hES cells (Fig. 1f) .
Xeno-free derivation and expansion of hES-MP cells
To derive hES-MP cells from a xeno-free hES cell line without contaminating the cell cultures with animal protein, all animal-derived components were replaced with humanderived or recombinant components. Human serum was used in the culture medium instead of FBS and human recombinant gelatin was used instead of porcine gelatin to coat culture dishes. Using these modified protocols, a xenofree hES-MP cell line was derived from the xeno-free hES cell line SA611 (Ellerström et al., 2006) . On removal from the supporting human foreskin fibroblast (hFF) feeder layer and transfer to high-density culture, the xeno-free hES cells initially showed an outgrowth pattern with less distinct three-dimensional structures. But already after two passages the arising xeno-free hES-MP cells were morphologically indistinguishable from the previously established non-xenofree lines (Figs. 1g, h) .
The protocols for the derivation of hES-MP cell lines showed excellent reproducibility and robustness. Multiple hES-MP cell lines were successfully derived and cultured from 10 different hES cell lines (number of establishments per cell line are shown in brackets), SA001(3), SA002 (3), SA002.5 (10), AS034 (2), AS034.1.1 (1), SA121 (6), SA167 (7), SA348 (1), SA461 (1), and SA611(1).
To exclude the possibility that the observed fast growing cell populations may actually be mouse embryonic fibroblasts that had not been sufficiently growth inactivated and had been transferred from the feeder layer by accident we performed immunostainings with an antibody specific for human nuclei on hES-MP cell cultures. These stainings clearly confirmed that all cells were human (Fig. 2) .
Characterization of hES-MPs cell lines
None of the markers typically found in undifferentiated hES cells (Oct-4, Nanog, TRA 1-60, TRA 1-81, SSEA-3, SSEA-4) nor the early differentiation marker SSEA-1 could be detected in hES-MP cell cultures in the proliferative state (Fig. 3) . Both endodermal markers (HNF3β and AFP) and neuroectodermal markers (nestin, GFAP, and β-III-tubulin) were undetectable. The epithelial markers E-cadherin and Pan-cytokeratin were also negative. However, the early mesodermal markers desmin and vimentin were clearly expressed in almost all cells, while α-smooth muscle actin (α-SMA) was expressed in individual cells in the proliferative state (Figs. 3a, c, e) . A high percentage (≥75%) of all four hES-MP cell lines analyzed (SA002, SA002.5, SA167, and SA461) as well as human MSCs were further positive for several markers characteristic for mesenchymal stem cells (CD105, CD166, CD10, CD13) and negative for the neuroprogenitor marker CD133 and the hematopoietic stem cell marker CD117 compared to undifferentiated hES cells analyzed by flow cytometry (Fig. 4) .
To allow bulk production, the hES-MP cells were cultured in flasks and passaged every 7 days at a split ratio of 1:10. At high densities when the cultures were ready for passage the hES-MP cells showed a more elongated morphology (Fig. 1d ).
Using this 7 day passage interval, the hES-MP cell lines could be expanded massively for 16-20 passages before a decrease in proliferative capacity was detected.
Differentiation and growth arrest could be induced in monolayer cultures by switching the hES-MP cell cultures to a serum-free hES-MP medium without hrbFGF, thus withdrawing mitogenic growth factors. Under those conditions proliferation of the hES-MP cells nearly halted within 14 days while the cell morphology became significantly more spread out and flattened. Cytoskeletal elements became more pronounced in phase contrast microscopy. The cells are still negative for ectodermal, endodermal, and epithelial markers while the mesodermal markers desmin and vimentin were highly expressed in almost all cells. Interestingly, an abundant expression of α-SMA was also detected (Figs. 3b, d, f) .
To evaluate whether hES-MP cells could be steered back to a less differentiated state by the signals which maintain pluripotency in hES cells, proliferating hES-MP cells were transferred to the traditional mouse embryonic fibroblast (MEF) feeder-layer-supported growth conditions for undifferentiated hES cells. Even under these conditions no evidence of de-differentiation could be found. The hES-MP cells rapidly formed a confluent monolayer while maintaining a mesenchymal morphology. No cells with undifferentiated hES cell morphology could be detected and immunocytochemical analysis, with the undifferentiated hES cell markers Oct-4, SSEA-1, and TRA-1-60, was negative (data not shown).
Transplantation of hES-MP cells
To examine the differentiation potential of the hES-MP cells in vivo and to assess the risk of tumor formation after transplantation, clusters of hES-MP cells were injected under the kidney capsule of SCID mice. After 8 weeks the mice were sacrificed and the kidneys were surgically removed. In each case the injected hES-MP cells had given rise to 1-to 2-mm oval tissue structures with sharp boundaries under the kidney capsule. The tissue formed by the hES-MP cells was macroscopically clearly visible, but very small compared to the massive teratoma which develops after transplantation of smaller numbers of undifferentiated hES cells (Heins et al., 2004 (Heins et al., , 2005 and reach an average size of 1-2 cm within 8 weeks. Obviously, growth of hES-MP cells after transplantation is very limited. Histological evaluation of the tissue which had developed from the injected cells showed various tissues of mesenchymal origin (Figs. 5a-e) . The presence of cartilage was confirmed by Alcian blue van Gieson and Safranin-O staining (Figs. 5b, c) .
The injected hES-MP cells had remained within a small, well-limited area at the injection site, and the developed tissue showed clearly defined boundaries toward the tissue of the mouse renal cortex. No sign of invasive growth into the surrounding tissue could be detected in serial cross sections. Even at the microscopical level no indication of teratoma formation from the transplanted hES-MP cells could be observed. All parental undifferentiated hES cell lines on the contrary formed teratoma (Heins et al., 2004 (Heins et al., , 2005 ; Ellerström et al., 2006) which comprised a mixture of tissues from all germ layers and showed invasive growth into the renal cortex (Fig. 5f) .
The human origin of the developed tissues was confirmed by whole genome human DNA-FISH on the cross sections of the tissue. Positive staining with the human probe was detected only in areas of tissue formation from the transplanted hES-MP cells, verifying that the hES-MP cells had human origin.
Chondrogenic differentiation
Differentiation of the hES-MP cell lines in Hyaff-11 scaffolds demonstrated cells evenly dispersed throughout the scaffold (Fig. 5a ). Microscopical evaluation revealed that the cells produced large amounts of matrix. Alcian blue van Gieson and Safranin-O stainings demonstrated the presence of sulfated proteoglycans characteristic for a cartilaginous matrix (Fig. 5a ). Accumulation of collagen type II was also detected (Figs. 5b, c) . Differentiation into the chondrogenic lineage for both hES-MP cells and MSCs was also performed using the high-density pellet mass culture system. Cartilage matrix was produced by the hES-MP cells also in this chondrogenic assay, although less accumulation of cartilage matrix was detected compared to that of the MSC pellets (Figs. 5d, e) .
Osteogenic differentiation
The osteogenic potential of the hES-MP cells as well as MSCs was demonstrated in a 2D culture system in which mineralization was studied using von Kossa staining (Figs. 6f, g ).
Adipogenic differentiation
After 25 days of incubation in adipogenic medium, the hES-MP cells changed morphology from a fibroblast-like to a more spherical shape. Adipogenic differentiation further resulted in lipid droplet formation characteristic for adipocytes as well as oil-red O-positive cells, although a larger population of MSCs differentiated toward the adipogenic lineage compared to that of the hES-MP cells (Figs. 6h, i ).
Discussion and conclusions
The aim of this study was to bring forth robust and reproducible protocols for the derivation of mesenchymal progenitors from hES cells primarily for the future use in tissue engineering and cell therapies. Nevertheless, easily derived and cultured cell lines with high human relevance have additional potential for drug discovery and toxicity testing, especially in screening applications.
The derivation of mesenchymal stem cell-like or fibroblast-like cells from hES cells using different protocols has been described earlier. The reported methods, for example, use transfection with human telomerase reverse transcriptase (Xu et al., 2004) , coculture with mouse OP9 cells (Barberi et al., 2005) , selection of cell populations by fluorescence-activated cell sorting (Lian et al., 2006) , or by manual selection of cell populations (Stojkovic et al., 2005; Olivier et al., 2006) . Neither of the protocols yet addresses the important aspects of xeno-free derivation, robustness, and safety for the use in tissue engineering and cell therapies. We here report the development of simplified protocols which do not require any of the above steps and allow quick and reproducible establishment of stable progenitor lines with the potential to give rise to derivates of the embryonic mesenchyme. The derivation method is based on highly selective culture conditions which result in morphologically homogeneous hES-MP populations within 2-3 passages. The high reproducibility of the method is demonstrated by the successful derivation of multiple hES-MP cell lines from a variety of parental hES cell lines.
An additional advantage of the present approach is that the protocols can be modified to allow the derivation and cultivation of hES-MP cells in the absence of animal-derived components. Other methods described so far involve, as described above, viral infection of exogenous DNA, coculture with animal-cells, or cell sorting using animal-derived monoclonal antibodies which makes the clinical suitability of these cell lines questionable. We were able to humanize our protocols to derive and expand a xeno-free hES-MP cell line from a xeno-free parental hES cell line (Ellerström et al., 2006 ) utilizing proven components and conditions which have been applied for the GMP-grade production of autologous chondrocytes for clinical use (Brittberg et al., 2003) . The hES-MP cell lines are easy to culture and have an excellent proliferative capacity. They can be grown on uncoated tissue culture plastic in a variety of formats and do not require feeder cells or conditioned medium. These characteristics make the cell lines suitable for largescale in vitro expansion. We demonstrate for the first time that the commonly used FBS (Barberi et al., 2005; Olivier et al., 2006) can be replaced by human serum to provide an animal-protein free environment for hES-MP cell expansion.
Mitogenic culture conditions can be used to maintain the hES-MP in a proliferative progenitor state over an extended period of time. Differentiation appears to occur only sporadically in individual cells which take on a more differentiated phenotype accompanied by the expression of alpha smooth muscle actin (α-SMA). Withdrawal of growth factors under serum-free conditions can be used to assist differentiation of the hES-MP cells in monolayer cultures. The hES-MP cultures enter growth arrest and take on a more mature phenotype indicated by dramatically increased α-SMA expression and a clear change in cell morphology while the marker profile remains exclusively mesodermal.
From a clinical point of view, cell therapy critically depends on a fine balance concerning the degree of differentiation of the cells to be transplanted. Grafted cells must be able to survive and form tissue, whereas tumorogenicity must be avoided under any circumstances. Bone-marrow-derived mesenchymal stem cells, for example, tend to show poor survival and integration after implantation to SCID mice (Thalmeier et al., 2001; Xia et al., 2004) while undifferentiated hES cells consistently give rise to tumors (Thomson et al., 1998; Heins et al., 2004) . No teratoma formation could be observed after transplantation of hES-MP cells into SCID mice. The small, well-defined connective tissues that developed from the transplanted hES-MP cells were distinctly different from the large, mixed germ-layer tumors which arise after transplantation of undifferentiated hES cells. These results are thus in accordance with the Mesenchymal stem cells can be isolated from the bone marrow and from other connective tissues, but availability depends on suitable donors and the proliferative properties (Hwang et al., 2006) and the long-term expandability of these cells in vitro is rather poor (Otto and Rao, 2004; Barberi et al., 2005) . The sophisticated infrastructure which is currently being built up for hES cell line banking, production, and distribution would allow the derivation of hES-MP cell lines from well-characterized hES cell lines with a wide variety of genetic backgrounds and specific properties. From any parental hES cell line, a virtually unlimited amount of genetically identical hES-MP cells could be produced for therapeutic purposes. Until possible immune compatibility problems between hES cell-derived cells and recipients are resolved, cell-based therapy may not be considered practical (Lian et al., 2006) . In the meantime, stable, easily handled progenitor lines nevertheless have a great potential as a unique source of highly consistent human cells for research, toxicity testing, and drug discovery (McNeish, 2004; Elisseff, 2004) as well as for the xeno-free in vitro production of human biologicals, ECM components, or human mesenchymal stem cell-derived cytokines (Caplan and Dennis, 2006) .
Materials and methods hES cell lines used
Ten different hES cell lines were used for the derivation of hES-MP cell lines. All hES cell lines had been established and characterized at Cellartis AB, Gothenburg, Sweden. The establishment, clonal derivation, characterization, and subsequent culture of hES cell lines SA001, SA002, SA002.5, AS034, AS034.1.1, SA121, SA167, SA348, and SA461 had been carried out as described previously (Heins et al., 2004 (Heins et al., , 2005 . The xeno-free hES cell line SA611 was established, expanded, and characterized as recently described (Ellerström et al., 2006) .
Derivation of hES-MP cell lines and subsequent expansion
Undifferentiated hES cells were removed from the supporting feeder layer, enzymatically dissociated with TrypLE Select (Gibco/Invitrogen, Paisley, UK), and plated onto 0.1% porcine gelatin-coated cell culture dishes (BD Falcon/BD Biosciences, Bedford, MA, USA) as high-density cultures at 1.5 × 10 5 cells/cm 2 in hES-MP medium consisting of DMEM-HG (with glutamax, without pyruvate) supplemented with 10% fetal bovine serum (FBS) and 10 ng/ml human recombinant basic fibroblast growth factor (hrbFGF) (all from Gibco/ Invitrogen). The plated hES cells were left to differentiate for 7 days in a humidified atmosphere at 37°C and 5% CO 2 resulting in an outgrowth of heterogeneous cell types. To initiate the derivation of hES-MP cells, the hES cells were then passaged enzymatically (passage 1, p1) as a single cell suspension using TrypLE Select to gelatin-coated culture dishes. In this and in all following passages or transfer steps, no selection was performed manually or otherwise; i.e., all cells were transferred. This procedure was repeated every 7 days until the cell population became homogeneous for hES-MP morphology (at p2-p3). Following the initial derivation steps, the hES-MP cells were cultured in uncoated tissue culture flasks (BD Falcon, BD Biosciences) in a humidified atmosphere at 37°C and 5% CO 2 and enzymatically passaged with TrypLE Select every 7 days at a split ratio of 1:10.
Xeno-free modifications for derivation and expansion of hES-MP cell lines
In order to derive a xeno-free hES-MP cell line, FBS was replaced with human serum (HS) in the hES-MP medium.
Human serum was prepared and tested as described earlier (Ellerström et al., 2006) . Human recombinant gelatin (Fibrogen, San Francisco, CA, USA) was used to coat culture dishes instead of porcine gelatin. Alternatively, noncoated tissue culture flasks were used for expansion with similar efficiency.
Isolation of human mesenchymal stem cells
Bone marrow was obtained from four patients undergoing spinal fusion (mean age 45 years, range 32-54). Mesenchymal stem cells were isolated from the bone marrow by gradient centrifugation using CPT tubes prefilled with Ficoll (Pharmacia, Uppsala, Sweden) according to manufacturer's instructions. The cells were then expanded in DMEM-LG (Invitrogen), supplemented with the same additives as described above for the expansion of hES-MP cells.
Flow cytometry analysis
The purity of the population of MSCs was evaluated using flow cytometry. MSCs in passage 3 were harvested at 80% confluence using 0.05% trypsin-0.53 mM EDTA (Gibco, Grand Island, NY, USA). These cells were then stained with antibodies against hematopoietic stem cells and endothelial cells (CD34), white blood cells (CD45), and MSCs (CD105, D166) (Ancell, Bayport, MN).
The phenotype of the hES-MP SA002, SA002.5, SA167, and SA461 cell lines and undifferentiated hES cell parental cell lines as well as human MSCs were studied by flow cytometry analysis for a panel of different markers (CD105, CD166 (both antibodies from Ancell, Bayport, MN), CD10, CD13, CD117, and CD133 (all four antibodies from BD Biosciences, Heidelberg, Germany)). Colonies of undifferentiated hES cells cultured on a supporting feeder layer were dissected out and treated with 0.05% trypsin-0.53 mM EDTA to obtain a single cell suspension. The hES-MP cells lines and human MSCs were expanded in monolayers as described above to 80% confluence and were then harvested using 0.05% trypsin-0.53 mM EDTA.
At least 10 000 events were acquired for each sample using the FACS Aria flow cytometer and the FACSDiVa software (Becton Dickinson). The 488 nm argon ion laser was used to excite samples, with emission being measured using appropriate bandpass filters. The cells were acquired and gated by forward (FSC) and side scatter (SSC) to exclude debris and cell aggregates. Dead cells were excluded by gating on FSC and SSC. To calculate the percentages of cells staining positive for each marker, a maximum of 2% positive cells stained with isotype control antibody was allowed.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde solution (Histolab Products AB, Västra Frölunda, Sweden) for 10 min at room temperature, permeabilized with 0.5% Triton X-100 (SigmaAldrich, St. Louis, MO, USA). Nonspecific binding of the antibodies was prevented by incubating the sections in 10% FBS in PBS (Gibco/Invitrogen) for 30 min before incubation with primary antibodies (Table 1a , supplementary data) for 20 h at 4°C, followed by a 1 h incubation with secondary antibodies (Table 1c , supplementary data) at 4°C. Negative controls were included in which the primary antibodies were omitted. Primary and secondary antibodies were purchased according to Table 1 (supplementary data) . DAPI (4′,6-diamidino-2-phenylindole) staining (Sigma-Aldrich), intercalating with the DNA was used to visualize cell nuclei in all antibody stainings.
Differentiation and tissue formation in vitro
In order to induce spontaneous differentiation in vitro of hES-MP cells in monolayer culture, hrbFGF was withdrawn from the hES-MP cell culture medium and FBS was replaced by SR (serum replacement, Gibco/Invitrogen). The cells were then left to differentiate for 14 days in a humidified atmosphere at 37°C and 5% CO 2 . Culture medium was renewed every 2-3 days. Phenotypical analysis was performed using immunohistochemistry as described above.
Osteogenic differentiation
Triplicate cultures of both hES-MP cells and human MSCs were seeded at a density of 4000 cells/cm 2 . The cells were cultured in DMEM-LG supplemented with 10% FBS, 80 μm ascorbic, acid-2-phosphate (Wako Chemicals, USA), 1 μM dexamethasone (Sigma-Aldrich), and 20 mM β-glycerol phosphate (Sigma-Aldrich).
After 5 weeks of culture, the cells were analyzed for mineralization with microscopic inspection and von Kossa staining. For von Kossa staining, the cells were first washed twice in PBS and fixed using Histofix for 30 min and again rinsed twice with water. The water was removed and 2% silver nitrate (Sigma-Aldrich) solution was added. The plate was kept in the dark for 10 min and then rinsed three times with water before being exposed to bright light for 15 min. The cells were rinsed twice and then quickly rehydrated in 100% EtOH.
Chondrogenic differentiation
The chondrogenic potential of the hES-MP cells and human MSCs was investigated using the high-density pellet mass culture system. Briefly, 4 × 10 5 cells were placed into a conical polypropylene tube. The cells were incubated in 0.5 ml of defined medium, consisting of DMEM-HG supplemented with 5.0 μg/ml linoleic acid (Sigma-Aldrich), 1X insulin, transferring, and selenium (ITS-G concentrate, Life Technologies, Paysley, UK), 1.0 mg/ml human serum albumin (Equitech-Bio, Kerrville, TX, USA), 10 -7 M dexamethasone, 14 μg/ml ascorbate acid (Sigma-Aldrich) 10% FBS, 20 ng/ml TGF-β1 (R&D Systems, Abingdon, UK), and 1% penicillinstreptomycin (PEST [PAA Laboratories]). The cells were centrifuged at 500g for 5 min and the medium was changed twice a week.
In order to study a possible clinical application of the hES-MP cells, culture of the cells in Hyaff-11 (Fidia Advanced Biopolymers, Abano Terme, Italy) scaffolds were performed. Cells from both hES-MP cell lines SA002.5 and SA167 were seeded in Hyaff-11 scaffolds prcoated with human serum at a cell density of 4 × 10 6 cells/cm 2 . The cells were cultured in the medium described above for 6 weeks.
After 6 weeks in Hyaff-11 cultures or 3 weeks in pellet mass cultures, the specimens were fixed in Histofix, dehydrated with EtOH, and embedded in paraffin. Fivemicrometer sections were cut and placed onto silane-coated glass slides. The sections were deparaffinized and stained with Safranin-O and Alcian blue van Gieson (HistoCenter) and were then observed with a light microscope (Nikon, Japan). The sections from the Hyaff-11 cultures were also used to immunohistochemically detect collagen type II. The sections were deparaffinized, dehydrated, digested with hyaluronidase, 8000 units/ml (Sigma-Aldrich) in PBS for 1 h at 37°C, and blocked with 3% BSA (Sigma-Aldrich). Sections were labeled with monoclonal antibodies raised against collagen type II (anti-collagen type II (ICN Biomedicals, Aurora, OH, USA)) diluted 1:150 in PBS containing 3% BSA. Primary antibodies were visualized using a HRP-conjugated secondary antibody (HRP-conjugated goat-anti-mouse) (Jackson Laboratory, Maine, ME, USA), diluted 1:150. All incubations were performed at room temperature in a humidified chamber for 1 h. Primary antibodies were visualized using the TSA-Direct Cy3 kit (Perkin Elmer, Boston, MA, USA) according to the manufacturer's instructions. After washing in PBS, nuclei were stained with DAPI (Sigma-Aldrich) and the slides were mounted in antifading medium. The sections were then analyzed with a Nikon fluorescence microscope and digital pictures were taken with the ACT-1 software. Positive controls were sections from goat hyaline cartilage obtained from the knee and negative controls were sections incubated with only secondary antibody.
Adipogenic differentiation
To induce adipogenesis, hES-MP cells derived from SA002.5 and SA167 as well as human MSCs were plated onto tissue culture treated 24-well plates at a seeding density of 10 4 cells/cm 2 . Triplicate cultures were incubated with DMEM-LG, 20% FBS, 5 μg/ml insulin, 10 -6 M dexamethasone, 0.5 mM isobutylmethylxanthin, and 60 μm indomethacin, all from Sigma-Aldrich, with medium changes twice a week.
After 25 days of culture, the cells were analyzed for lipid content with microscopic inspection and oil-red O staining (Merck, Darmstadt, Germany). For oil-red O staining, the cells were washed in PBS and fixed in Histofix for 10 min. The cells were then stained with oil-red O solution (in 60% isopropanol) for 1 h followed by repeated washings with water.
Dedifferentiation of hES-MP cells
hES-MP cells were enzymatically removed from the culture dishes using TrypLE Select and seeded onto a growthinactivated MEF feeder cell layer in VitroHES supplemented with 4 ng/ml hrbFGF. The cocultures were incubated for 10 days in a humidified atmosphere at 37°C and 5% CO 2 . Culture medium was renewed every 2-3 days.
In vivo differentiation
For assessment of the safety aspects concerning transplantation of the hES-MP cells for use in therapies and tissue engineering as well as to examine the in vivo differentiation potential of the hES-MP cells, four of the different hES-MP cell lines were examined in vivo (SA001, SA002.5, AS034, and SA121). The transplantations were done repeatedly with the hES-MP cell lines between passage 5-15 and repeated in 2-8 mice for every cell line. Approximately 200 000 hES-MP cells were mechanically scraped loose from the culture plate and surgically placed under the kidney capsule of 5-week-old SCID (severe combined immunodeficiency) mice (CB-17/lcrCrl-Scid, Sulzfeld, Charles River Laboratories, Germany). The mice were sacrificed after 8 weeks and the kidneys were surgically removed. All animal studies had been reviewed and approved by the Institutional Animal Care and Use Committee at Göteborg University in accordance with the policy regarding the use and care of laboratory animals. The tissue samples were then fixed in 4% paraformaldehyde solution (HistoLab Products AB) for 24 h and embedded in paraffin. The tissue samples were sectioned at a thickness of 6-9 μm and were evaluated histologically following hematoxylin-eosin and Safranin O staining (HistoCenter).
Confirmation of human origin
To confirm the human origin of the tissues developed under the fibrous capsule of the mouse kidneys, a whole genome human DNA-FISH probe (Spectrum Red-labeled total human genomic DNA, Vysis Inc, Downers Grove, IL, USA) was used to exclusively label human cell nuclei as described previously (Gertow et al., 2004) .
